Is NCT06622005 recruiting in Buffalo, NY?

Yes, NCT06622005 is currently recruiting participants at its Buffalo, NY location. This recurrent multiple myeloma clinical trial is actively enrolling qualified participants.

How do I join the recurrent multiple myeloma clinical trial in Buffalo?

To join this clinical trial in Buffalo, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Buffalo clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Recurrent Multiple Myeloma Clinical Trial in Buffalo, NY

About This Recurrent Multiple Myeloma Study in Buffalo

This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells. Blocking those specific sites allows other cells of the immune system to become "free" to kill tumor cells. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells, while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection. Dexamethasone is in a class of medications called corticosteroids. It is known to kill myeloma cells and is also used to reduce inflammation and lower the body's immune response to monoclonal antibodies like dratumumab and help lessen its side effects. Giving SX-682 in combination with carfilzomib, daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma

Sponsor: Roswell Park Cancer Institute

Who Can Participate

Inclusion Criteria

Confirmed relapsed/ refractory multiple myeloma

Measurable disease including at least one of the following criteria:

Serum M-protein ≥ 0.5 g/dL

Urine M-protein ≥ 200 mg/24h

Serum free light chain assay: involved free light chain (FLC) level greater or equal to 100 mg/L provided serum free light chain ratio is abnormal

Bone marrow plasma cells ≥ 10% total bone marrow cells

≥ 1 prior line of therapy

Planned treatment with a carfilzomib/daratumumab/dexamethasone regimen

Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Absolute neutrophil count: ≥ 3 x 10\^9/L

Platelets: ≥ 75 x 10\^9/L

Hemoglobin: ≥ 7 g/dL

Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome

Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) / alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \[SGPT\]): ≤ 3 x ULN

Renal Function: Estimated creatinine clearance ≥ 45 mL/min (Cockroft-Gault)

Left ventricular ejection fraction of at least 50%

Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 6 months following the last dose of the investigational drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

Participant must understand the investigational nature of this study and sign an Independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria

Patients with non-secretory myeloma, systemic light chain amyloidosis or, plasmacytoma

Intolerance to SX-682 or any other of the treatment components

Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 days after completion of treatment)

Refractory to prior daratumumab (i.e. relapse or progression on or within 60 days after completion of treatment)

Concomitant medication(s) known to be (a) a strong inhibitor or inducer of CYP3A4, or (b) QT prolonging as defined in the drug's approved label, with the exception of drugs that are considered absolutely essential for the care of the subject or if the investigator believes that beginning therapy with such medication is vital to an individual subject's care while on study, and in either case, there is no alternative medication

Electrocardiogram (ECG) demonstrating a corrected QT (QTc) interval \> 470 msec or patients with congenital long QT syndrome

Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure in the last 6 months

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, class III or IV heart failure (New York Heart Association functional classification system) or psychiatric illness/social situations that would limit compliance with study requirements

History of hepatitis B, C or HIV

Known active bacillus tuberculosis infection

Pregnant or nursing female participants

Unwilling or unable to follow protocol requirements

Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Buffalo?

Yes, this clinical trial (NCT06622005) has an active research site in Buffalo, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Multiple Myeloma Treatment Options in Buffalo, NY

If you're searching for recurrent multiple myeloma treatment options in Buffalo, NY, this clinical trial (NCT06622005) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Buffalo research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent multiple myeloma clinical trials near you to find additional studies recruiting in your area.

Recurrent Multiple Myeloma Clinical Trial in Buffalo, NY

Expert Care in Buffalo

IRB Approved

No-Cost Care

Apply for This Buffalo Location

Why Participate?

Simple Process